Title	Computed tomography analysis of the association between the SH2B1 rs7498665 single-nucleotide polymorphism and visceral fat area.
Author(s)	Hotta, Kikuko; Kitamoto, Takuya; Kitamoto, Aya; Mizusawa, Seiho; Matsuo, Tomoaki; Nakata, Yoshio; Hyogo, Hideyuki; Ochi, Hidenori; Kamohara, Seika; Miyatake, Nobuyuki; Kotani, Kazuaki; Komatsu, Ryoya; Itoh, Naoto; Mineo, Ikuo; Wada, Jun; Yoneda, Masato; Nakajima, Atsushi; Funahashi, Tohru; Miyazaki, Shigeru; Tokunaga, Katsuto; Masuzaki, Hiroaki; Ueno, Takato; Chayama, Kazuaki; Hamaguchi, Kazuyuki; Yamada, Kentaro; Hanafusa, Toshiaki; Oikawa, Shinichi; Yoshimatsu, Hironobu; Sakata, Toshiie; Tanaka, Kiyoji; Matsuzawa, Yuji; Nakao, Kazuwa; Sekine, Akihiro
Citation	Journal of human genetics (2011), 56(10): 716-719
Issue Date	2011-10
URL	http://hdl.handle.net/2433/189864
Right	© 2014 The Japan Society of Human Genetics
Type	Journal Article
Textversion	author

Computed tomography analysis of the association between the *SH2B1* rs7498665 single

nucleotide polymorphism and visceral fat area

Kikuko Hotta[1], Takuya Kitamoto[1], Aya Kitamoto[1], Seiho Mizusawa[2], Tomoaki Matsuo[3], Yoshio Nakata[3], Hideyuki Hyogo[4], Hidenori Ochi[4], Seika Kamohara[5], Nobuyuki Miyatake[6], Kazuaki Kotani[7], Ryoya Komatsu[8], Naoto Itoh[9], Ikuo Mineo[10], Jun Wada[11], Masato Yoneda[12], Atsushi Nakajima[12], Tohru Funahashi[13], Shigeru Miyazaki[14], Katsuto Tokunaga[15], Hiroaki Masuzaki[16], Takato Ueno[17], Kazuaki Chayama[4], Kazuyuki Hamaguchi[18], Kentaro Yamada[19], Toshiaki Hanafusa[20], Shinichi Oikawa[21], Hironobu Yoshimatsu[22], Toshiie Sakata[22], Kiyoji Tanaka[3], Yuji Matsuzawa[7], Kazuwa Nakao[1, 23] and Akihiro Sekine[1, 2]

[1]EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan; [2]Center for Genomic Medicine, Unit of Genome Informatics, Kyoto University Graduate School of Medicine, Kyoto, Japan; [3]Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; [4]Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; [5]Health Science University, Yamanashi, Japan; [6]Department of Hygiene, Faculty of Medicine, Kagawa University, Kagawa, Japan; [7]Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan; [8]Rinku General Medical Center, Osaka, Japan; [9]Toyonaka Municipal Hospital, Osaka, Japan; [10]Otemae Hospital, Osaka, Japan; [11]Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; [12]Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; [13]Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Osaka, Japan; [14]Tokyo Postal Services Agency Hospital, Tokyo, Japan; [15]Itami City Hospital, Hyogo, Japan; [16]Division of Endocrinology and Metabolism, Second Department of Internal Medicine, University of the Ryukyus Faculty of Medicine, Okinawa, Japan; [17]Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan; [18]Department of Community Health and Gerontological Nursing, Faculty of Medicine, Oita University, Oita, Japan; [19]Division of Endocrinology and Metabolism, Department of Medicine, Kurume University, Kurume, Japan; [20]Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan; [21]Division of Endocrinology and Metabolism, Department of Medicine, Nippon Medical School, Tokyo, Japan; [22]Department of Internal Medicine 1, Faculty

of Medicine, Oita University, Oita, Japan; [23]Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan

Corresponding author:

Kikuko Hotta, M.D., Ph.D.

Assistant Professor

EBM Research Center, Kyoto University Graduate School of Medicine

Yoshida-Konoecho, Sakyo-ku

Kyoto 606-8501, Japan

Phone: +81-75-751-2022

Fax: +81-75-751-2082

E-mail: kikukoh@kuhp.kyoto-u.ac.jp

Running title: *SH2B1* rs7498665 SNP and visceral fat area

ABSTRACT

Visceral fat accumulation plays an important role in increasing morbidity and mortality rate by increasing the risk of developing several metabolic disorders, such as type 2 diabetes, dyslipidemia, and hypertension. New genetic loci that contribute to the development of obesity have been identified by genome-wide association studies in Caucasian populations. We genotyped 1279 Japanese subjects (556 men and 723 women), who underwent computed tomography (CT) for measuring visceral fat area (VFA) and subcutaneous fat area (SFA), for the following single nucleotide polymorphisms (SNPs): *NEGR1* rs2815752, *SEC16B* rs10913469, *TMEM18* rs6548238, *ETV5* rs7647305, *GNPDA2* rs10938397, *BDNF* rs6265 and rs925946, *MTCH2* rs10838738, *SH2B1* rs7498665, *MAF* rs1424233, and *KCTD15* rs29941 and rs11084753. In the additive model, none of the SNPs were significantly associated with BMI. The *SH2B1* rs7498665 risk allele was found to be significantly associated with VFA ($P = 0.00047$) but not with BMI or SFA. When the analysis was performed in men and women separately, no significant associations with VFA were observed ($P = 0.0099$ in men and $P = 0.022$ in women). None of the other SNPs were significantly associated with SFA. Our results suggest that there is a VFA-specific genetic factor and that a polymorphism in the *SH2B1* gene influences the risk of visceral fat accumulation.

INTRODUCTION

Obesity, especially visceral fat obesity, is a risk factor for several metabolic disorders, including

type 2 diabetes, dyslipidemia, and hypertension.[1]   Several studies have indicated that adipose

tissue, especially that in the visceral region, secretes various adipocytokines and that an increase

in adipose tissue mass leads to alteration in the plasma levels of adipocytokines, resulting in the

development of dyslipidemia, hypertension, and insulin resistance.[2, 3]   Intra-abdominal fat

accumulation (central adiposity) is determined in terms of waist circumference; waist-hip ratio;

or visceral fat area (VFA), which is measured using computed tomography (CT).[1, 4, 5]   Recently,

2 genome-wide association studies (GWASs) were conducted to identify the loci linked with

waist circumference and waist-hip ratio.[6, 7]   In a previous study, we have reported that the

rs1558902 and rs1421085 genotypes of the fat mass and obesity associated gene (*FTO*) were

significantly associated with VFA as well as with subcutaneous fat area (SFA) and body mass

index (BMI).[8]

       We performed a large-scale, case-control association study and found that

secretogranin III (*SCG3*)[9] and myotubularin-related protein 9 (*MTMR9*)[10] conferred

susceptibility to an obese phenotype in the Japanese population.   Recent progress in GWASs

has increased the number of known genetic susceptibility loci for obesity.[11-13]   Some of the

obesity-associated loci identified by the GWAS were found to be replicated in the Japanese

population.[14,15]　Some of the obesity-related loci were found to overlap with the waist circumference- waist-hip ratio-related loci, for example, the loci within the *FTO* gene and near the melanocortin 4 receptor (*MC4R*) gene.

In this study, we investigated whether the recently reported obesity-related loci were associated with VFA, which is an important factor responsible for increased morbidity and mortality rates.

MATERIALS AND METHODS

Study subjects

In this study, we enrolled 1279 Japanese subjects from outpatient clinics; these patients had agreed to undergo CT testing (in the supine position) to determine the VFA and SFA values at the umbilical level (L4–L5).　Both VFA and SFA values were calculated using the FatScan software program (N2system, Osaka, Japan).[16]　The patients visited the hospitals to undergo the treatment for obesity and/or metabolic abnormalities such as hypertension, dyslipidemia, and type 2 diabetes.　Patients with secondary obesity and obesity-related hereditary disorders were excluded from this study.　Patients with disease or under treatment that strongly affect the body weight were also excluded.　The clinical data were taken at the first visit to the hospital. The clinical characteristics of the subjects are summarized in Table 1.　Metabolic syndrome

and metabolic abnormalities were diagnosed according to the criteria released by the Japanese

Committee for the Diagnostic Criteria of Metabolic Syndrome in April 2005.[4, 5]   Written

informed consent was obtained from each subject, and the protocol was approved by the ethics

committee of each institution and by that of Kyoto University.

DNA extraction and single nucleotide polymorphism genotyping

Genomic DNA was extracted from the blood samples collected from each subject by using

Genomix (Talent Srl, Trieste, Italy).   We selected 12 single nucleotide polymorphisms (SNPs)

identified as susceptibility loci for obesity by GWASs in Caucasian populations[11-13] and

constructed Invader probes (Third Wave Technologies, Madison, WI, USA) for the following

SNPs: rs2815752 in the neuronal growth regulator 1 gene (*NEGR1*); rs10913469 in the SEC16

homolog B gene (*SEC16B*); rs6548238 in the transmembrane protein 18 gene (*TMEM18*);

rs7647305 in the ets variant 5 gene (*ETV5*); rs10938397 in the glucosamine-6-phosphate

deaminase 2 gene (*GNPDA2*); rs6265 and rs925946 in the brain-derived neurotrophic factor

gene (*BDNF*); rs10838738 in the mitochondrial carrier homolog 2 gene (*MTCH2*); rs7498665 in

the SH2B adaptor protein 1 gene (*SH2B1*); rs1424233 in the v-maf musculo-aponeurotic

fibrosarcoma oncogene homolog gene (*MAF*); and rs29941 and rs11084753 in the potassium

channel tetramerisation domain containing 15 gene (*KCTD15*).   The SNPs were genotyped

using Invader assays as previously described.[17]   The success rate of these assays was >99.0%.

Statistical analysis

For the additive model, we coded the genotypes as 0, 1, or 2 depending on the number of copies of the risk alleles. For the dominant model, homozygosity and heterozygosity with the risk allele were coded as 1 and the other was coded as 0. Multiple linear regression analyses were performed to test the independent effect of the risk alleles on BMI, VFA, and SFA by taking into account the effects of other variables (i.e., age and gender) that were assumed to be independent of the effect of each SNP. The Hardy–Weinberg equilibrium was assessed using the χ^2-test.[18] Statistical analysis was performed using the software R (http://www.r-project.org/). P–values were corrected by Bonferroni adjustment and $P < 0.0042$ (0.05/12) was considered statistically significant.

RESULTS

The clinical characteristics and genotypes of the subjects are shown in Tables 1 and 2, respectively. All the SNPs were in the Hardy–Weinberg equilibrium. The BMI, VFA, and SFA values for each SNP genotype are represented in Table 3. Multiple linear regression analyses of the anthropometric parameters with respect to the 12 SNPs analyzed are shown in Table 4. No SNPs were not significantly associated with BMI in this population, though a previous study reported that the *SEC16B* rs109134 and *TMEM18* rs6548238 SNPs were

significantly associated with obesity (BMI > 30 kg m^{-2}) in the Japanese population.[15]

The *SH2B1* rs7498665 SNP was significantly associated with VFA ($P = 0.00047$) even when the conservative Bonferroni's correction was applied ($P < 0.0042$). Previous reports indicate that the rs7498665 SNP is associated with waist circumference[19] or visceral fat mass[20] in the dominant model. The VFA values of the rs7498665 genotype (Table 3) suggest that the dominant model would be best fitted model. Therefore, we performed multiple regression analyses by using the dominant model and found a significant association between this SNP and VFA ($P = 0.00022$). This association remained significant even after adjusting for age, gender, and BMI in the dominant model ($P = 0.00096$). The other SNPs did not show any significant association with VFA. No SNPs, including the *SH2B1* rs7498665, were associated with SFA.

BMI, VFA and SFA are known to be affected by gender; therefore, we compared the anthropometric parameters (BMI, VFA and SFA) among the different genotypes in the men and women (Supplementary Table 1, 2 and 3). Association between *SH2B1* rs7498665 SNP and VFA was not significant both in men ($P = 0.0099$) and women ($P = 0.022$). This negative association is most likely due to the decrease in the number of each genotype. The VFA values of the rs7498665 genotype (Supplementary Table 2) suggest that the dominant model would be best fitted model both in men and women. By using the dominant model revealed no significant association between the rs7498665 genotype and VFA in men ($P = 0.0061$) and

9

women ($P = 0.015$).

To confirm the association of the *SH2B1* rs7498665 SNP with VFA, 2 SNPs (rs4788102 and rs8049439) in linkage disequilibrium of rs7498665 reported by previous study[11] were genotyped (Supplementary Table 4). Both rs4788102 ($P = 0.00058$) and rs8049439 ($P = 0.0021$) SNPs were significantly associated with VFA.

DISCUSSION

In this study, we showed that the *SH2B1* rs7498665 SNP was significantly associated with VFA. Haupt *et al.* used whole-body magnetic resonance imaging (MRI) to show that this SNP (dominant model) was associated with visceral fat mass.[20] They also reported that the *SH2B1* rs7498665 SNP was not associated with BMI or with nonvisceral fat mass. Jamshidi *et al.* reported that the *SH2B1* rs7498665 SNP (dominant model) was associated with waist circumference.[19] Several studies have reported a negative association between the *SH2B1* rs7498665 SNP and abdominal adipose mass (measured using dual energy X-ray absorptiometry [DEXA])[21] or waist circumference.[22, 23] CT- or MRI-based analyses are more accurate than waist circumference- and DEXA-based abdominal fat mass analysis for evaluating the association between this SNP and visceral fat mass. The data from this study and from the study performed by Haupt *et al.* strongly suggest that the *SH2B1* rs7498665 SNP is associated

with visceral fat accumulation.

SH2B1 has 4 splicing isoforms, i.e., α, β, γ, and δ, of which SH2-Bβ was originally identified through its association with Janus kinase 2 (JAK2) protein, a cytoplasmic tyrosine kinease that mediates cytokine actions.[24] *SH2B1*-knockout mice have been reported to show severely impaired insulin signaling in the skeletal muscles, liver, and adipose tissue and progressively develop hyperinsulinemia, hyperglycemia, and glucose intolerance.[25] *SH2B1*-knockout mice also developed hyperlipidemia, leptin resistance, hyperphagia, and obesity.[26] Although data for mesenteric fat has not been reported, both subcutaneous inguinal fat and intra-abdominal (epididymal) fat were found to be increased in *SH2B1*-knockout mice.[26, 27] Neuron-specific restoration of *SH2B1* in knockout mice corrected the metabolic disorders, improved leptin regulation of orexigenic neuropeptide expression in the hypothalamus, and protected against high-fat diet-induced leptin resistance and obesity.[27] Ventromedial hypothalamic (VMH) lesions are reported to induce visceral fat accumulation that does not result in obesity, and to induce hyperglycemia, hyperinsulinemia, and hypertriglyceridemia.[28] *SH2B1* was specifically expressed in the brain, including the hypothalamus, in mice with neuron-specific *SH2B1* restoration.[27] Therefore, *SH2B1* expression in hypothalamus (possibly the VMH) may play an important role in visceral fat accumulation. Since the *SH2B1* rs7498665 SNP is a non-synonymous SNP (G/A, Ala484Thr) and exits in the proline-rich region,

the function of the SH2B1 protein might be deteriorated in subjects with the risk G-allele, leading to visceral fat accumulation.   The rs4788102 SNP exists in the 5′-flanking region of the *SH2B1* gene, thus, the expression of *SH2B1* may be changed in the subjects with the risk A-allele.   It is necessary to investigate whether these SNPs are functional.

In summary, we showed that the *SH2B1* rs7498665 SNP is significantly associated with VFA.   This SNP is not associated with BMI or SFA, suggesting that there is a VFA-specific genetic factor.   Our results also suggest that the *SH2B1* gene plays a role in visceral fat accumulation.   However, these results need to be confirmed in other populations.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ACKNOWLEDGEMENTS

REFERNECS

1. Carr, D. B., Utzschneider, K. M., Hull, R. L., Kodama, K., Retzlaff, B. M., Brunzell, J. D. *et al.* Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* **53**, 2087–2094 (2004).

2. Matsuzawa, Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. *Nat. Clin. Pract. Cardiovasc. Med.* **3**, 35–42 (2006).

3. Hotta, K., Funahashi, T., Bodkin, N. L., Ortmeyer, H. K., Arita, Y., Hansen, B. C. *et al.* Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. *Diabetes* **50**, 1126–1133 (2001).

4. Mastuzawa, Y. Metabolic syndrome-definition and diagnostic criteria in Japan. *J. Atheroscler. Thromb.* **12**, 301 (2005).

5. Arai, H., Yamamoto, A., Matsuzawa, Y., Saito, Y., Yamada, N., Oikawa, S. *et al.* Prevalence of metabolic syndrome in the general Japanese population in 2000. *J. Atheroscler. Thromb.* **13**, 202–208 (2006).

6. Lindgren, C. M., Heid, I. M., Randall, J. C., Lamina, C., Steinthorsdottir, V., Qi, L. *et al.* Genome-wide association scan meta-analysis identifies three loci influencing

adiposity and fat distribution. *PLoS Genet.* **5**, e1000508 (2009).

7. Heard-Costa, N. L., Zillikens, M. C., Monda, K. L., Johansson, A., Harris, T. B., Fu, M. *et al.* NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. *PLoS Genet.* **5**, e1000539 (2009).

8. Hotta, K., Nakamura, M., Nakamura, T., Matsuo, T., Nakata, Y., Kamohara, S. *et al.* Polymorphisms in NRXN3, TFAP2B, MSRA, LYPLAL1, FTO and MC4R and their effect on visceral fat area in the Japanese population. *J. Hum. Genet.* **55,** 738–742 (2010).

9. Tanabe, A., Yanagiya, T., Iida, A., Saito, S., Sekine, A., Takahashi, A. *et al.* Functional single-nucleotide polymorphisms in the secretogranin III (SCG3) gene that form secretory granules with appetite-related neuropeptides are associated with obesity. *J. Clin. Endocrinol. Metab.* **92**, 1145–1154 (2007).

10. Yanagiya, T., Tanabe, A., Iida, A., Saito, S., Sekine, A., Takahashi, A. *et al.* Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. *Hum. Mol. Genet.* **16,** 3017–3026 (2007).

11. Thorleifsson, G., Walters, G. B., Gudbjartsson, D. F., Steinthorsdottir, V., Sulem, P., Helgadottir, A. *et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat. Genet.* **41**, 18–24 (2009).

12. Willer, C. J., Speliotes, E. K., Loos, R. J., Li, S., Lindgren, C. M., Heid, I. M. *et al.* Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat. Genet.* **41**, 25–34 (2009).

13. Meyre, D., Delplanque, J., Chèvre, J. C., Lecoeur, C., Lobbens, S., Gallina, S. *et al.* Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat. Genet.* **41**, 157–159 (2009).

14. Hotta, K., Nakata, Y., Matsuo, T., Kamohara, S., Kotani, K., Komatsu, R. *et al.* Variations in the FTO gene are associated with severe obesity in the Japanese. *J. Hum. Genet.* **53**, 546–553 (2008).

15. Hotta, K., Nakamura, M., Nakamura, T., Matsuo, T., Nakata, Y., Kamohara, S. *et al.* Association between obesity and polymorphisms in SEC16B, TMEM18, GNPDA2, BDNF, FAIM2 and MC4R in a Japanese population. *J. Hum. Genet.* **54**, 727–731 (2009).

16. Yoshizumi, T., Nakamura, T., Yamane, M., Islam, A. H., Menju, M., Yamasaki, K., *et al.* Abdominal fat: standardized technique for measurement at CT. *Radiology* **211**, 283–286 (1999).

17. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. & Nakamura, Y. A high-throughput SNP typing system for genome-wide association studies. *J. Hum. Genet.* **46**, 471-477 (2001).

18. Nielsen, D. M., Ehm, M. G. & Weir, B. S. Detecting marker-disease association by testing for Hardy–Weinberg disequilibrium at a marker locus. *Am. J. Hum. Genet.* **63**, 1531–1540 (1998).

19. Jamshidi, Y., Snieder, H., Ge, D., Spector, T. D., O'Dell, S. D. The SH2B gene is associated with serum leptin and body fat in normal female twins. *Obesity* **15**, 5-9 (2007).

20. Haupt, A., Thamer, C., Heni, M., Machicao, F., Machann, J., Schick, F., et al. Novel obesity risk loci do not determine distribution of body fat depots: a whole-body MRI/MRS study. *Obesity* **18**, 1212-1217 (2010).

21. Renström, F., Payne, F., Nordström, A., Brito, E. C., Rolandsson, O., Hallmans, G., *et al.* Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. *Hum. Mol. Genet*. **18**, 1489-1496 (2009).

22. Bauer, F., Elbers, C. C., Adan, R. A., Loos, R. J., Onland-Moret, N. C., Grobbee, D. E., et al. Obesity genes identified in genome-wide association studies are associated with adiposity measures and potentially with nutrient-specific food preference. *Am. J. Clin. Nutr.* **90**, 951-959 (2009).

23. Ng, M. C., Tam, C. H., So, W. Y., Ho, J. S., Chan, A. W., Lee, H. M., *et al.* Implication of genetic variants near NEGR1, SEC16B, TMEM18, ETV5/DGKG, GNPDA2, LIN7C/BDNF, MTCH2, BCDIN3D/FAIM2, SH2B1, FTO, MC4R, and KCTD15 with

obesity and type 2 diabetes in 7705 Chinese. *J. Clin. Endocrinol. Metab.* **95**, 2418-2425, (2010).

24. Rui, L., Mathews, L. S., Hotta, K., Gustafson, T. A. & Carter-Su, C. Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. *Mol. Cell. Biol.* **17**, 6633-6644 (1997).

25. Duan, C., Yang, H., White, M. F. & Rui, L. Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. *Mol. Cell. Biol.* **24,** 7435-7443 (2004).

26. Ren, D., Li, M., Duan, C. & Rui, L. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. *Cell Metab.* **2**, 95-104 (2005).

27. Ren, D., Zhou, Y., Morris, D., Li, M., Li, Z. & Rui, L. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. *J. Clin. Invest.* **117**, 397-406 (2007).

28. Yoshida, S., Yamashita, S., Tokunaga, K., Yamane, M., Shinohara, E., Keno, Y., et al. Visceral fat accumulation and vascular complications associated with VMH lesioning of spontaneously non-insulin-dependent diabetic GK rat. Int. *J. Obes. Relat. Metab. Disord.* **20**, 909-916 (1996).

Table 1   Clinical characteristics of the subjects

	Men	Women	Total
n	556	723	1279
Age (years)	49.4 ± 12.2	52.2 ± 11.3	51.0 ± 11.8
BMI (kg m^{-2})	30.2 ± 6.1	28.1 ± 5.3	29.0 ± 5.8
VFA (cm^2)	155.3 ± 67.7	99.8 ± 53.6	123.9 ± 66.1
SFA (cm^2)	206.7 ± 108.6	241.6 ± 97.2	226.5 ± 103.7
Waist circumference (cm)	97.5 ± 11.3	91.8 ± 10.3	94.2 ± 11.1
Prevalence of metabolic disease			
Dyslipidemia	293 (53%)	244 (34%)	537 (42%)
Hypertension	379 (68%)	452 (63%)	831 (65%)
Impaired fasting glucose	177 (32%)	176 (24%)	353 (28%)
Metabolic syndrome	248 (45%)	162 (22%)	410 (32%)

Data are shown as mean ± s.d.

Table 2　Genotypic characteristics of the subjects

SNP ID	Nearby gene	Allele 1/2	Risk allele	Genotype	HWE *P*-value
rs2815752	*NEGR1*	A/G	A	1113/163/3	0.24
rs10913469	*SEC16B*	T/C	C	690/510/78	0.20
rs6548238	*TMEM18*	T/C	C	6/201/1071	0.29
rs7647305	*ETV5*	C/T	C	201/576/500	0.10
rs10938397	*GNPDA2*	A/G	G	615/537/126	0.58
rs6265	*BDNF*	A/G (Met/Val)	G	207/609/462	0.79
rs925946	*BDNF*	T/G	T	3/100/1175	0.57
rs10838738	*MTCH2*	G/A	G	107/555/616	0.25
rs7498665	*SH2B1*	G/A (Ala/Thr)	G	29/305/945	0.46
rs1424233	*MAF*	C/G	C	726/469/82	0.59
rs29941	*KCTD15*	T/C	C	774/444/60	0.72
rs11084753	*KCTD15*	G/A	G	105/535/638	0.63

HWE, Hardy-Weinberg equilibrium.

Table 3　Mean BMI, VFA, and SFA for 12 obesity-risk variants

		Mean ± SD								
	Nearby	BMI (kg m^{-2})			VFA (cm^2)			SFA (cm^2)		
SNP ID	gene	11	12	22	11	12	22	11	12	22
rs2815752	*NEGR1*	29.1 ± 5.9	28.3 ± 5.3	28.5 ± 3.1	124.8 ± 66.7	118.5 ± 62.6	95.2 ± 38.8	226.1 ± 103.1	228.3 ± 108.5	251.0 ± 79.8
rs10913469	*SEC16B*	28.8 ± 5.9	29.2 ± 5.6	29.7 ± 6.5	123.0 ± 66.4	124.9 ± 65.2	124.8 ± 70.4	221.7 ± 103.7	231.6 ± 102.6	234.0 ± 110.5
rs6548238	*TMEM18*	25.9 ± 7.5	29.0 ± 7.2	29.0 ± 5.5	85.9 ± 70.6	123.4 ± 67.1	124.3 ± 65.9	211.0 ± 135.0	222.8 ± 111.3	227.3 ± 102.2
rs7647305	*ETV5*	29.0 ± 5.3	29.1 ± 5.4	29.0 ± 6.3	124.5 ± 66.8	124.5 ± 66.3	123.2 ± 65.8	234.1 ± 99.5	225.6 ± 100.0	224.6 ± 109.6
rs10938397	*GNPDA2*	28.8 ± 5.9	29.1 ± 5.8	29.2 ± 5.3	122.7 ± 68.0	124.5 ± 64.0	127.4 ± 66.3	224.5 ± 103.4	227.9 ± 103.3	229.3 ± 107.5
rs6265	*BDNF*	28.6 ± 5.9	28.7 ± 5.3	29.6 ± 6.3	122.4 ± 68.2	122.9 ± 64.7	126.1 ± 67.1	220.3 ± 92.9	223.5 ± 102.2	233.2 ± 109.9
rs925946	*BDNF*	36.0 ± 10.7	29.5 ± 6.1	28.9 ± 5.7	142.6 ± 11.3	123.3 ± 63.3	124.0 ± 66.4	416.8 ± 155.7	236.3 ± 118.6	225.2 ± 101.9
rs10838738	*MTCH2*	28.7 ± 4.9	29.3 ± 6.4	28.7 ± 5.3	124.5 ± 58.3	125.1 ± 68.5	122.6 ± 65.2	214.1 ± 93.1	233.6 ± 109.6	222.2 ± 99.8
rs7498665	*SH2B1*	29.7 ± 4.8	29.5 ± 6.2	28.8 ± 5.7	134.4 ± 65.3	134.5 ± 70.5	120.2 ± 64.3	231.1 ± 95.9	235.1 ± 98.4	223.6 ± 105.5
rs1424233	*MAF*	29.0 ± 6.0	29.1 ± 5.7	28.4 ± 3.8	123.1 ± 64.7	124.0 ± 65.7	130.6 ± 80.4	222.0 ± 102.6	234.0 ± 109.1	219.7 ± 74.5
rs29941	*KCTD15*	28.8 ± 5.6	29.1 ± 6.0	30.4 ± 6.0	123.9 ± 65.2	122.4 ± 67.3	136.5 ± 68.5	224.8 ± 103.7	228.2 ± 103.5	236.6 ± 106.6
rs11084753	*KCTD15*	29.5 ± 5.7	29.1 ± 5.8	28.9 ± 5.8	128.3 ± 71.9	122.5 ± 64.9	124.5 ± 66.2	233.0 ± 98.6	227.4 ± 102.0	224.7 ± 106.1

11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.　　Allele1 and allele2 in each SNP is indicated in Table2.

Table 4　Relationship between obesity loci and adiposity measures

SNP ID	Nearby gene	BMI			VFA			SFA		
		β	SE	*P*-value	β	SE	*P*-value	β	SE	*P*-value
rs2815752	*NEGR1*	0.611	0.448	0.17	7.423	4.847	0.13	-6.293	7.978	0.43
rs10913469	*SEC16B*	0.325	0.255	0.20	2.827	2.753	0.30	4.516	4.532	0.32
rs6548238	*TMEM18*	0.267	0.403	0.51	6.773	4.352	0.12	2.557	7.178	0.72
rs7647305	*ETV5*	0.025	0.221	0.91	1.984	2.386	0.41	2.565	3.929	0.51
rs10938397	*GNPDA2*	0.199	0.236	0.40	0.804	2.547	0.75	4.065	4.190	0.33
rs6265	*BDNF*	0.508	0.223	0.023	1.390	2.410	0.56	6.954	3.968	0.080
rs925946	*BDNF*	0.816	0.545	0.14	0.390	5.897	0.95	18.972	9.685	0.050
rs10838738	*MTCH2*	0.162	0.243	0.51	0.292	2.628	0.91	2.726	4.326	0.53
rs7498665	*SH2B1*	0.536	0.310	0.085	11.717	3.343	0.00047	8.341	5.555	0.13
rs1424233	*MAF*	0.050	0.252	0.84	-2.945	2.722	0.28	-5.311	4.479	0.24
rs29941	*KCTD15*	0.481	0.265	0.070	2.588	2.871	0.37	3.589	4.727	0.45
rs11084753	*KCTD15*	0.332	0.243	0.17	1.562	2.626	0.55	3.242	4.322	0.45

Data were derived from a linear regression analysis.　BMI, VFA, and SFA were adjusted for age and gender.

Supplementary Table 1   Genotypic characteristics of the subjects in men and women

SNP ID	Nearby gene	Allele1/2	Risk allele	Men		Women	
				Genotype	HWE *P*-value	Genotype	HWE *P*-value
rs2815752	*NEGR1*	A/G	A	484/71/1	0.33	629/92/2	0.48
rs10913469	*SEC16B*	T/C	C	307/215/34	0.65	383/295/44	0.19
rs6548238	*TMEM18*	T/C	C	2/101/453	0.14	4/100/618	0.98
rs7647305	*ETV5*	T/C	C	81/252/222	0.49	120/324/278	0.12
rs10938397	*GNPDA2*	A/G	G	257/241/57	0.96	358/296/69	0.49
rs6265	*BDNF*	A/G	G	88/259/209	0.60	119/350/253	0.91
rs925946	*BDNF*	T/G	T	0/47/509	0.30	3/53/666	0.09
rs10838738	*MTCH2*	G/A	G	51/246/258	0.48	56/309/358	0.34
rs7498665	*SH2B1*	G/A	G	13/135/408	0.65	16/170/537	0.56
rs1424233	*MAF*	A/G	A	321/200/35	0.61	405/269/47	0.80
rs29941	*KCTD15*	T/C	C	341/190/25	0.82	433/254/35	0.77
rs11084753	*KCTD15*	G/A	G	44/222/290	0.87	61/313/348	0.42

HWE, Hardy-Weinberg equilibrium.

Supplementary Table 2   Mean BMI, VFA, and SFA for 12 obesity-risk variants in men and women

SNP ID	Nearby gene	Gender	BMI (kg m^{-2}) 11	BMI 12	BMI 22	VFA (cm^2) 11	VFA 12	VFA 22	SFA (cm^2) 11	SFA 12	SFA 22
						Mean ± SD					
rs2815752	*NEGR1*	Men	30.3 ± 6.2	29.5 ± 5.8	30.4	156.4 ± 67.9	148.9 ± 66.2	78.5	206.2 ± 107.3	210.8 ± 118.2	173.8
		Women	28.2 ± 5.4	27.3 ± 4.7	27.6 ± 3.7	100.4 ± 54.4	95.1 ± 48.3	103.6 ± 50.8	241.5 ± 97.1	241.7 ± 99.0	289.6 ± 61.5
rs10913469	*SEC16B*	Men	30.0 ± 6.5	30.3 ± 5.6	31.2 ± 5.4	154.4 ± 69.4	156.9 ± 63.8	153.5 ± 77.3	202.2 ± 107.8	211.7 ± 110.9	216.5 ± 102.0
		Women	27.8 ± 5.1	28.4 ± 5.4	28.6 ± 7.1	97.8 ± 51.7	101.6 ± 55.6	102.5 ± 56.0	237.4 ± 97.7	246.1 ± 93.6	247.5 ± 116.0
rs6548238	*TMEM18*	Men	31.2 ± 11.6	30.4 ± 8.8	30.1 ± 5.4	122.2 ± 114.3	149.5 ± 70.4	156.8 ± 67.0	274.2 ± 237.3	207.1 ± 125.6	206.4 ± 104.2
		Women	23.3 ± 4.6	27.7 ± 4.7	28.2 ± 5.4	67.8 ± 51.4	97.0 ± 51.9	100.5 ± 53.9	179.4 ± 87.4	238.5 ± 92.8	242.7 ± 97.9
rs7647305	*ETV5*	Men	30.4 ± 5.2	30.3 ± 5.8	29.9 ± 6.8	156.8 ± 67.3	155.2 ± 68.2	155.1 ± 67.7	223.4 ± 112.4	204.9 ± 107.7	202.9 ± 108.3
		Women	28.0 ± 5.2	28.1 ± 4.9	28.2 ± 5.9	102.8 ± 57.1	100.6 ± 53.9	97.7 ± 51.7	241.3 ± 89.6	241.6 ± 90.6	242.1 ± 107.6
rs10938397	*GNPDA2*	Men	30.0 ± 6.5	30.4 ± 6.1	30.1 ± 4.4	155.0 ± 71.5	156.0 ± 63.4	154.5 ± 69.6	201.9 ± 111.0	210.0 ± 106.0	213.2 ± 109.7
		Women	28.0 ± 5.2	28.1 ± 5.4	28.4 ± 5.8	99.5 ± 54.7	98.9 ± 52.1	105.0 ± 54.5	240.6 ± 94.6	242.6 ± 98.9	242.7 ± 104.6
rs6265	*BDNF*	Men	29.8 ± 5.9	29.9 ± 5.9	30.6 ± 6.5	156.9 ± 62.2	152.3 ± 68.0	158.5 ± 69.7	201.7 ± 94.8	200.8 ± 109.7	216.3 ± 112.3
		Women	27.7 ± 5.7	27.8 ± 4.7	28.7 ± 5.9	96.9 ± 61.0	101.2 ± 52.6	99.3 ± 51.4	234.1 ± 89.5	240.4 ± 92.9	247.2 ± 106.1
rs925946	*BDNF*	Men	–	31.4 ± 5.9	30.0 ± 6.1	–	156.3 ± 59.6	155.2 ± 68.5	–	233.9 ± 119.0	204.2 ± 107.4
		Women	36.0 ± 10.7	27.9 ± 5.9	28.1 ± 5.2	142.6 ± 11.3	94.1 ± 51.2	100.1 ± 53.8	416.8 ± 155.7	238.5 ± 119.4	241.2 ± 94.4
rs10838738	*MTCH2*	Men	29.6 ± 5.4	30.4 ± 7.0	30.0 ± 5.4	144.4 ± 63.4	159.0 ± 71.1	153.8 ± 65.1	178.9 ± 87.1	213.0 ± 111.4	206.3 ± 109.4
		Women	28.0 ± 4.4	28.5 ± 5.9	27.8 ± 5.0	106.4 ± 46.7	98.2 ± 52.6	100.1 ± 55.4	246.2 ± 87.1	250.1 ± 105.4	233.6 ± 90.7

			11	12	22	11	12	22	11	12	22
rs7498665	*SH2B1*	Men	31.3 ± 5.4	30.9 ± 7.2	29.9 ± 5.7	165.9 ± 73.5	168.5 ± 69.5	150.6 ± 66.5	213.7 ± 120.9	222.6 ± 104.6	201.3 ± 109.3
		Women	28.3 ± 3.9	28.4 ± 5.1	28.0 ± 5.5	108.7 ± 45.6	107.6 ± 58.9	97.0 ± 51.8	246.2 ± 68.5	244.9 ± 92.3	240.5 ± 99.5
rs1424233	*MAF*	Men	30.2 ± 6.9	30.3 ± 5.1	29.0 ± 3.7	153.5 ± 65.7	156.3 ± 65.2	167.2 ± 95.3	203.2 ± 111.5	215.2 ± 109.6	191.4 ± 65.8
		Women	28.0 ± 5.0	28.3 ± 6.0	27.9 ± 3.8	98.9 ± 52.7	99.9 ± 54.9	103.4 ± 53.8	236.9 ± 92.4	248.1 ± 106.8	240.7 ± 74.2
rs29941	*KCTD15*	Men	30.0 ± 5.8	30.5 ± 6.8	29.9 ± 4.7	154.3 ± 65.7	156.1 ± 70.5	164.3 ± 74.4	204.3 ± 106.7	211.6 ± 114.1	203.3 ± 92.0
		Women	27.9 ± 5.2	28.1 ± 5.2	30.7 ± 6.8	100.1 ± 54.0	97.1 ± 52.1	116.7 ± 57.1	240.9 ± 98.4	240.6 ± 93.1	260.3 ± 111.0
rs11084753	*KCTD15*	Men	29.5 ± 5.1	30.3 ± 6.4	30.1 ± 6.0	158.9 ± 81.5	153.5 ± 66.3	156.2 ± 66.7	207.7 ± 100.0	207.7 ± 109.7	205.8 ± 109.4
		Women	29.5 ± 6.2	28.2 ± 5.1	27.8 ± 5.4	106.2 ± 54.9	100.5 ± 54.0	98.1 ± 53.0	251.3 ± 94.3	241.3 ± 93.9	240.5 ± 100.7

11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.   Allele1 and allele2 in each SNP is indicated in Supplementary Table1.

Supplementary Table 3   Relationship between obesity loci and adiposity measures in men and women

SNP ID	Nearby gene	Gender	BMI			VFA			SFA		
			β	SE	*P*-value	β	SE	*P*-value	β	SE	*P*-value
rs2815752	*NEGR1*	Men	0.412	0.724	0.57	9.582	8.386	0.25	-8.762	12.782	0.49
		Women	0.746	0.564	0.19	5.661	5.653	0.32	-4.606	10.135	0.65
rs10913469	*SEC16B*	Men	0.360	0.407	0.38	1.132	4.716	0.81	6.421	7.182	0.37
		Women	0.338	0.323	0.30	4.531	3.236	0.16	3.451	5.810	0.55
rs6548238	*TMEM18*	Men	-0.322	0.619	0.60	8.070	7.173	0.26	-2.593	10.976	0.81
		Women	0.811	0.526	0.12	5.788	5.280	0.27	7.388	9.469	0.44
rs7647305	*ETV5*	Men	0.174	0.358	0.63	0.740	4.154	0.86	6.997	6.322	0.27
		Women	-0.090	0.276	0.75	2.832	2.768	0.31	-0.768	4.972	0.88
rs10938397	*GNPDA2*	Men	0.188	0.376	0.62	0.186	4.363	0.97	6.480	6.645	0.33
		Women	0.192	0.299	0.52	1.141	2.993	0.70	2.063	5.364	0.70
rs6265	*BDNF*	Men	0.490	0.355	0.17	1.927	4.121	0.64	9.648	6.281	0.13
		Women	0.553	0.283	0.051	1.257	2.836	0.66	5.199	5.091	0.31
rs925946	*BDNF*	Men	1.156	0.891	0.20	1.254	10.343	0.90	26.135	15.711	0.097
		Women	0.554	0.678	0.42	-0.411	6.807	0.95	13.655	12.190	0.26
rs10838738	*MTCH2*	Men	-0.022	0.385	0.95	-0.774	4.456	0.86	-6.099	6.790	0.37
		Women	0.317	0.311	0.31	1.239	3.113	0.69	9.960	5.571	0.074

rs7498665	*SH2B1*	Men	0.761	0.493	0.12	14.734	5.692	0.0099	13.960	8.717	0.11
		Women	0.333	0.395	0.40	9.102	3.949	0.022	3.603	7.170	0.62
rs1424233	*MAF*	Men	0.246	0.405	0.54	-4.845	4.688	0.30	-3.566	7.148	0.62
		Women	-0.100	0.319	0.75	-1.504	3.183	0.64	-6.676	5.704	0.24
rs29941	*KCTD15*	Men	0.205	0.428	0.63	3.185	4.965	0.52	3.179	7.570	0.68
		Women	0.689	0.333	0.039	2.119	3.348	0.53	3.844	6.006	0.52
rs11084753	*KCTD15*	Men	-0.064	0.390	0.87	-0.483	4.520	0.92	2.266	6.885	0.74
		Women	0.639	0.306	0.037	3.154	3.073	0.31	3.997	5.513	0.47

Data were derived from a linear regression analysis.   BMI, VFA, and SFA were adjusted for age.

Supplementary Table 4   Relationship between SNPs in *SH2B1* loci and adiposity measures

SNP ID	Position (build 36.3)	Allele 1/2	Risk allele	Genotype	BMI β (SE)	BMI *P*-value	VFA β (SE)	VFA *P*-value	SFA β (SE)	SFA *P*-value	D′/r^2
rs8049439	28745016	C/T	C	71/475/731	0.628 (0.258)	0.015	8.582 (2.781)	0.0021	7.653 (4.599)	0.096	1.00/0.51
rs4788102	28780899	A/G	A	29/304/944	0.530 (0.311)	0.088	11.546 (3.347)	0.00058	8.018 (5.561)	0.15	1.00/1.00
rs7498665	28790742	G/A	G	29/305/945	0.536 (0.310)	0.085	11.717 (3.343)	0.00047	8.341 (5.555)	0.13	–

Data were derived from a linear regression analysis.   BMI, VFA, and SFA were adjusted for age and gender.